Home

Verily Accelerates Precision Health AI With NVIDIA

via Business Wire

NVIDIA’s software and accelerated computing will be integrated across Verily’s Pre platform. NVIDIA NeMo, NVIDIA Parabricks, and NVIDIA CUDA-X Data Science are now available in Verily Workbench, with accelerated workflows powered by NVIDIA Blackwell.

The NVIDIA-enhanced Pre platform will be used in the NIH All of Us Researcher Workbench, which supports nearly 20K registered researchers.

Verily, a precision health AI company, today announced a collaboration with NVIDIA to integrate NVIDIA’s AI technology stack into its Pre platform, which is used by health system, life science, payer, and government customers and partners to more efficiently develop and deploy AI across healthcare.

Verily has added NVIDIA’s GPU-accelerated libraries and frameworks, including NVIDIA NeMo, NVIDIA Parabricks, and NVIDIA CUDA-X Data Science within Workbench, Verily’s trusted research environment (TRE). Researchers also now have access to some of the latest GPUs including NVIDIA Blackwell and NVIDIA Hopper. This integration has shown to greatly accelerate analyses, from hours to minutes, when using Parabricks and B200 to process genomic data as compared to traditional, CPU-only methods.

This effort will accelerate analyses within the National Institutes of Health’s (NIH) All of Us Researcher Workbench, which will be powered by Pre through Verily’s partnership with Vanderbilt University Medical Center. The All of Us Researcher Workbench hosts one of the world’s largest genomics datasets and supports nearly 20,000 registered researchers globally.

In addition to the Workbench integration, Verily plans to make NVIDIA GPU-accelerated microservices, libraries, and frameworks available for use across other Pre solutions. This includes Refinery, a powerful curation engine that ingests, harmonizes, and enriches multimodal data, using a clinically informed, FHIR-native data model to transform unstructured data into structured data assets, and Exchange, a secure forum for sharing and accessing AI-ready datasets, models, and agents to advance precision research and care.

“This collaboration is an exciting moment as we partner with our customers to deliver on the promise of precision health,“ said Stephen Gillett, Verily CEO. “With NVIDIA's cutting-edge AI capabilities now available in our Pre platform, we are providing researchers with unparalleled tools to enhance the speed and efficiency of AI model development and omics analysis, ultimately accelerating the understanding of disease and advancing precision health for everyone."

"AI is a critical tool for advancing precision health,” said Trent Norris, Global Industry Leader for Digital Health at NVIDIA. “Integrating NVIDIA's accelerated infrastructure and software stack into Verily's Pre platform will empower researchers to unlock new insights and drive faster development of AI models — ultimately leading to more personalized medicine and earlier disease prediction."

As a demonstration of the power of the Pre platform enhanced with NVIDIA AI tools, Verily's researchers have developed the first multimodal foundation model using the NIH All of Us Research Program dataset. The model integrates electronic health records (EHR) and genomics through polygenic risk scores, moving beyond traditional EHR-only approaches to build a more holistic individual health profile, enabling new insights into disease prediction and proactive health management. Using NVIDIA NeMo Automodel and H100 GPUs Verily researchers were able to train the model 10x faster than previous approaches.

About Verily

Verily is a data platform and technology company purpose-built to power AI for precision health. Verily offers AI-enabled solutions that transform multimodal health data into insights and actions that accelerate research and improve care for individuals and communities. Verily is uniquely positioned at the intersection of technology, data science, and healthcare to create tools that accelerate evidence generation, enable more personalized care, and help manage disease at a population level. For more information about Verily please visit: verily.com.

Contacts